Sanofi to review its new eczema drug amlitelimab - Meet them in May

Corvus shares nearly triple on positive data for eczema pill

An immune drug developer raises $50M to finance its eczema drug testing

Nektar sees silver lining as autoimmune drug ‘narrowly’ misses in alopecia study - Meet them in May

J&J eyes $100B in sales amid gains for cancer, immune drugs - Meet them in May

Alumis soars as TYK2 drug hits mark in psoriasis trials - Meet them in May

Galapagos TYK2 drug hits goal in one trial, misses in another

Takeda says $4B TYK2 drug succeeds in large psoriasis studies

Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study

Connect’s Dupixent challenger hits the mark in phase 3 eczema trial

Apogee strengthens case for longer-lasting eczema drug

DE-RISKING EARLY CLINICAL STRATEGY IN DERMATOLOGY: FROM FIRST INDICATION SELECTION TO ROBUST CONFIRMATORY EVIDENCE